Published online before print February 16, 2004, doi: 10.1161/01.CIR.0000112596.06954.00
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2004;109:904-910.)
© 2004 American Heart Association, Inc.
Basic Science Reports |
Endothelin-1–Induced Cardiac Hypertrophy Is Inhibited by Activation of Peroxisome Proliferator–Activated Receptor-
Partly Via Blockade of c-Jun NH2-Terminal Kinase Pathway
From the Cardiovascular Division, Department of Internal Medicine, Institute of Clinical Medicine (Y.I.-T., T.M., S.S., T.O., M.T., M.I., I.Y.) and Department of Pharmacology, Institute of Basic Medical Sciences (K.G.), University of Tsukuba, Tsukuba, Ibaraki; Graduate School of Medicine, Chiba University (Y.K.), Inohana, Ciba; and The Institute of Physical and Chemical Research (RIKEN) (T.S.), Wako, Saitama, Japan.
Correspondence to Takashi Miyauchi, MD, PhD, Cardiovascular Division, Department of Internal Medicine, Institute of Clinical Medicine, University of Tsukuba, Tsukuba, Ibaraki 305-8575, Japan. E-mail t-miyauc{at}md.tsukuba.ac.jp
Received April 18, 2002; de novo received November 21, 2002; revision received October 15, 2003; accepted October 16, 2003.
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Background— Peroxisome proliferator-activated receptor-
(PPAR-) is a lipid-activated nuclear receptor that negatively regulates the vascular inflammatory gene response by interacting with transcription factors, nuclear factor-
B, and AP-1. However, the roles of PPAR- activators in endothelin (ET)-1–induced cardiac hypertrophy are not yet known.
Methods and Results— First, in cultured neonatal rat cardiomyocytes, a PPAR- activator, fenofibrate (10 µmol/L), and PPAR- overexpression markedly inhibited the ET-1–induced increase in protein synthesis. Second, fenofibrate markedly inhibited ET-1–induced increase in c-Jun gene expression and phosphorylation of c-Jun and JNK. These results suggest that this PPAR- activator interferes with the formation and activation of AP-1 protein induced by ET-1 in cardiomyocytes. Third, fenofibrate significantly inhibited the increase of ET-1 mRNA level by ET-1, which was also confirmed by luciferase assay. Electrophoretic mobility shift assay revealed that fenofibrate significantly decreased the ET-1–stimulated or phorbol 12-myristate 13-acetate–stimulated AP-1 DNA binding activity, and the nuclear extract probe complex was supershifted by anti-c-Jun antibody. Fourth, 24 hours after aortic banding (AB) operation, fenofibrate treatment significantly inhibited left ventricular hypertrophy and hypertrophy-related gene expression pattern (ET-1, brain natriuretic peptide, and ß-myosin heavy chain mRNA) in AB rats.
Conclusions— These results suggest that PPAR- activation interferes with the signaling pathway of ET-1–induced cardiac hypertrophy through negative regulation of AP-1 binding activity, partly via inhibition of the JNK pathway in cultured cardiomyocytes. We also revealed that fenofibrate treatment inhibited left ventricle hypertrophy and phenotypic changes in cardiac gene expression in AB rats in vivo.
Key Words: endothelin • hypertrophy • signal transduction
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Peroxisome proliferator-activated receptor-
(PPAR-) is abundant in tissues with high oxidative energy demands that depend on mitochondrial fatty acid oxidation as a primary energy source, such as the heart and liver.1 Fibric acid derivatives including fenofibrate are thought to act as specific activators of PPAR-.2 PPAR- together with PPAR-
and PPAR-
form a subgroup within the nuclear receptor superfamily.3 PPARs regulate gene expression by binding with retinoid X receptors as a heterodimeric partner to peroxisome proliferator response elements.4 Recently, Yamamoto et al5 demonstrated that PPAR- activators inhibit mechanical strain–induced hypertrophy in cardiomyocytes. However, it is unclear how PPAR- activation contributes to the development of cardiac hypertrophy.
Endothelin (ET)-1, a potent vasoconstrictor peptide from vascular endothelial cells,6 is also synthesized and secreted by cardiomyocytes6 and induces hypertrophy of cardiomyocytes6,7 through activating phospholipase C, protein kinase C, extracellular signal-regulated kinase (ERK) 1 and ERK2, and upregulation of c-Fos and c-Jun. ET-1 is moderately effective in activating JNK8 and p38.9 Upregulation of preproET-1 mRNA expression is induced by several stimuli that activate protein kinase C, such as angiotensin II, ET-1 itself, phorbol ester, and stretch.10 The ET-1 gene has AP-1 binding sites in the promoter region, and these factors are known to upregulate AP-1, suggesting that the ET-1 gene is partly induced through AP-1 binding.6 We have reported that the production of ET-1 is markedly increased both in the hypertrophied heart and the failing heart11–14 and that chronic treatment with ET type A receptor antagonists significantly inhibited the development of cardiac hypertrophy and heart failure.11,13,14 These data suggest that ET-1 plays an important role in the development of cardiac hypertrophy and heart failure, both in vitro and in vivo. However, the roles of PPAR- activators in ET-1–induced cardiac hypertrophy are not yet known. The present study was designed to examine this question.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Primary Culture of Rat Cardiomyocytes
As described previously,7,15 ventricular cardiac myocytes were isolated from 2- to 3-day-old Sprague-Dawley rats, cultured in DMEM/Ham F12 medium supplemented with 0.1% fatty acid–free BSA (Sigma) for 2 days, and then used for additional experiments.
RNA Extraction and Reverse Transcription–Polymerase Chain Reaction
Total RNA from cardiomyocytes or the left ventricle (LV) was isolated as described previously.14,15 The mRNA level was analyzed by reverse transcription–polymerase chain reaction (RT-PCR). RT-PCR for ET-1 and brain natriuretic peptide (BNP) was performed according to our previous report.14 The expression of GAPDH and ß-actin was also determined as an internal control. The sequences of the specific primers were as follows: c-Fos (sense), 5'CTTTCCTACTACCATTCCCCAG3'; c-Fos (antisense), 5'GCAGCCATCTTATTCCTTTCCC3'; c-Jun (sense), 5'AACTCGGACCTTCTCACGTCG3'; and c-Jun (antisense), 5'TGCTGAGGTTGGCGTA- GACC3'. Distinction between -myosin heavy chain (MHC) and ß-MHC was determined by our previous method.14
In Vitro Experiments
Cardiac Myocyte Surface Area
Cell images captured by CCD Camera (Olympus) were traced and analyzed with NIH image 1.56. The area was then doubled to account for the surface portion in contact with the dish. All cells (102 cells in total) from randomly selected fields in 2 or 3 dishes were examined for each condition.
Cloning and Expression of PPAR-
Rat PPAR- was cloned from rat cardiomyocytes cDNA using the following primers: PPAR- (sense), 5'CGGGATCCATGGTGGACACAGAGA3'; PPAR- (antisense), 5'GGATCCGTACATGTCTCTGTAG3'. After sequence analysis, the PCR product was cloned into the mammalian expression vector phrGFP (STRATAGENE, North Torrey) to obtain a C-terminal PPAR- green fluorescent protein (GFP) construct (PPAR--phrGFP).
For transient transfections, cardiomyocytes in 24-well plates (density, 105 cells/well) were transiently transfected with 0.2 µg of PPAR--phrGFP plasmid or phrGFP plasmid (as transfection control) using LipofectANIME (LIFE TECHNOLOGIES) according to the manufacturer’s instructions.
Protein Synthetic Rate
Protein synthesis in cultured neonatal rat ventricular myocytes was assessed as described previously.7
Expressions of c-Fos, c-Jun, and preproET-1 mRNA
Cardiomyocytes were pretreated with 0.1% DMSO or fenofibrate (10 µmol/L) for 1 hour, with PD98059 (20 µmol/L) (MEK1/2 inhibitor) for 15 minutes, and stimulated with ET-1 (100 nmol/L) for 15 or 30 minutes. The mRNA levels of c-Fos, c-Jun, and preproET-1 were analyzed by RT-PCR as described above.
Western Blot Analysis
Cardiomyocytes were pretreated with 0.1% DMSO or fenofibrate (10 µmol/L) for 1 hour and stimulated with ET-1 (100 nmol/L) for the time indicated. Western blot analysis for total cell lysates was performed by using antisera to phosphoERK1/2, ERK1/2, phospho-c-Jun (Ser73), c-Jun and JNK, and phospho-JNK (Thr183/Tyr185) G9 monoclonal antibody (Cell Signaling Technology Inc).
Luciferase Assay
Cardiomyocytes were transiently transfected with the following ET-1 luciferase reporter constructs: pET-1-Luc and pmET-1-Luc by LipofectANIME method. The pET-1-Luc construct includes 5'-flanking region of rat ET-1 promoter (810 bp corresponding to -750 to +60) containing AP-1 consensus DNA-binding site (-109 to -102).15 To generate pmET-1-Luc construct, the AP-1 binding site (5'-GTGACTAA-3') was changed into 5'GTGTGTAA-3' by Quick Change site-directed mutagenesis kit (STRATAGENE, North Torrey). Transfected cardiomyocytes were cultured for 
24 to 26 hours and treated with fenofibrate for 1 hour. Then ET-1 (100 nmol/L) or phorbol 12-myristate 13-acetate (PMA) (SIGMA-ALDRICH, USA) (100 nmol/L) was added for 3 hours. Cells were harvested, and luciferase activity was measured as described previously.15
Nuclear Extracts and EMSA
Nuclear extracts of cardiomyocytes were prepared as described previously.16 Cardiomyocytes were stimulated for 30 minutes with PMA (100 nmol/L) or ET-1 (100 nmol/L) with or without fenofibrate pretreatment (1 hour) before nuclear extracts preparation. Double-stranded oligonucleotide probes containing the AP-1 consensus sequence [5'-d(CGCTTGATGAGTCAGCCGGAA)-3'] (Promega) or mutant AP-1 sequence [5'-d(CGCTTGATGACTTGGC- CGGAA)-3'] (mAP-1) were end-labeled with [-32P]-ATP (3000 Ci/mmol; NEN Life Science Products Inc) according to standard protocols. Protein-DNA complex was separated from free DNA probe by electrophoresis in a nondenaturing 4% polyacrylamide gel in x0.5 Tris-Borate-EDTA at 4°C and analyzed by BAS 5000 (Fuji Film Ltd). Nonlabeled double-stranded oligonucleotides corresponding to AP-1 binding site were used as specific competitor DNAs. For supershift experiments, 200 ng of goat polyclonal c-Jun/AP-1 (N)-G affinity–purified IgG (Santa Cruz Biotechnology) was used.
In Vivo Experiments
Rats With Cardiac Hypertrophy Attributable to Aortic Banding
Rats were orally administered fenofibrate (80 mg/kg per d) (Kaken Seiyaku Ltd) or vehicle (3% arabic gum) (Wako Ltd) for 1 week before surgery.17 The operation of aortic banding was carried out according to the method described by Jouannot and Hatt18 and Yorikane et al12 with minor modification. This animal study was approved by the University of Tsukuba and conformed to the Position of the American Heart Association on Research Animal Use.
Hemodynamic Measurement, Tissue Sampling, and mRNA Expression
Twenty-four hours after surgery, the hemodynamic parameter of each rat and the ratio of LV wet weight to body weight (BW) (LV mass index for BW) were measured according to our previous reports.11–14 The expression of preproET-1 and BNP mRNA and the transition of -MHC to ß-MHC mRNA, the alterations of which are regarded as molecular markers of cardiac hypertrophy, were investigated according to our previous report.14 The expression of 18 S ribosomal RNA was determined as an internal control.
Data Analysis
Data were expressed as mean±SEM. One-way ANOVA followed by a post hoc test was used for statistical comparison among the various treatment groups. Differences were considered significant at P<0.05.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
In Vitro Experiments
Inhibitory Effect of Fenofibrate and PPAR-
Overexpression on Cardiomyocytes Hypertrophy-Induced by ET-1As shown in Figure 1A, ET-1 significantly increased enlargement of cardiomyocytes (1.8-fold versus control, n=100 cells, P<0.0001). A PPAR-
activator, fenofibrate (10 µmol/L), significantly inhibited the effect (-64%, n=100 cells, P<0.0005). Fenofibrate (10 µmol/L) by itself did not affect the myocyte surface area (n=100 cells). Leucine uptake was significantly increased by ET-1 (1.8±4.0-fold versus control, n=4, Figure 1B), and this was inhibited by fenofibrate in a concentration-dependent manner (5 and 10 µmol/L; -20% at 5 µmol/L, n=10; -28% at 10 µmol/L, n=10). Fenofibrate by itself did not affect basal levels of leucine incorporation (n=10, Figure 1B). Overexpression of PPAR- also inhibited ET-1–induced leucine uptake in cardiomyocytes (Figure 1C).
|
P<0.01 vs ET-1 (0.1 nmol/L), 
P<0.05 vs ET-1+fenofibrate (5 µmol/L). NS indicates not significant vs control (open column). C, Inhibitory effects of PPAR-
Effect of Fenofibrate on c-Fos and c-Jun mRNA Expression Induced by ET-1
We investigated the effect of fenofibrate on ET-1–stimulated expression of immediate early genes such as c-Fos and c-Jun, which are known to be the AP-1 components. ET-1 increased the levels of c-Fos and c-Jun mRNA (Figures 2A and 2B). The increase in c-Fos mRNA level was inhibited by MEK1/2 inhibitor, PD98059 (20 µmol/L), but not fenofibrate (10 µmol/L). In contrast, the increase in c-Jun mRNA level was inhibited by fenofibrate but not PD98059 (Figure 2B). Moreover, c-Jun protein level was increased after 15, 30, and 60 minutes of ET-1 stimulation (Figure 3A), which was also inhibited by fenofibrate (Figure 3A).
|
P<0.05 vs ET-1 (100 nmol/L), ||P<0.05 vs ET-1+fenofibrate.
|
Effect of Fenofibrate on ET-1–Induced Phosphorylation of c-Jun and JNK
To additionally elucidate the counter effect of fenofibrate on AP-1, we determined whether fenofibrate affected the JNK/c-Jun pathway. The level of phosphorylation on Ser73 of c-Jun was increased after 15, 30, and 60 minutes of ET-1 stimulation, which was markedly inhibited by fenofibrate (Figures 3B and 3C). Fenofibrate did not affect phosphorylation of c-Jun without ET-1 (Figures 3B and 3C). As shown in Figure 4A, ET-1 (100 nmol/L) markedly induced the phosphorylation of JNKs (JNK1/2 at 54 KDa/46 KDa), which was significantly inhibited by fenofibrate. Neither application of ET-1 nor fenofibrate treatment affected the expression level of JNKs in cardiomyocytes.
|
Effects of Fenofibrate on ET-1–Induced ERK1/2 Phosphorylation
As described in previous reports, ERK activation, a sensitive and quantitative marker for hypertrophic responses to external stimuli, is strongly activated by ET-1 in cardiomyocytes.10 Also in this study, ET-1 (100 nmol/L) induced the phosphorylation of ERKs in cardiomyocytes. This was not inhibited by fenofibrate (10 µmol/L) (Figure 4B). Neither application of ET-1 nor fenofibrate treatment affected the expression level of ERKs in cardiomyocytes.
Effect of Fenofibrate on PreproET-1 mRNA Expression and ET-1 Gene Promoter Activity Induced by ET-1
As shown in Table 1, ET-1 (100 nmol/L) by itself increased ET-1 mRNA level in cardiomyocytes (308.6±17.9% versus control, P<0.05), which was inhibited by fenofibrate (1, 5, and 10 µmol/L) in a dose-dependent manner (165.3±14.5%, 106.0±1.0%, and 83.3±9.9% versus ET-1, P<0.05). Then luciferase assay was performed using pET-1-Luc or pmET-1-Luc constructs to elucidate whether fenofibrate transcriptionally regulates ET-1 gene expression via the AP-1 site (Table 2). In the presence of pET-1-Luc, luciferase activity was increased in cells exposed to ET-1 (100 nmol/L) (9.4±0.6 versus 0.3±0.1 light unit, P<0.05), which was reduced by the pretreatment with fenofibrate (10 µmol/L) for 1 hour (by 4.7±0.4 light unit, P<0.05). Compared with the case of pET-1-Luc, ET-1–induced luciferase activity in cells transfected with pmET-1-Luc was markedly suppressed with or without fenofibrate treatment (3.8±0.8 and 3.6±0.3 light unit, respectively, both P<0.05 versus pET-1 ET-1 [+]). These results suggest that fenofibrate negatively regulates the AP-1–dependent ET-1 gene transcription.
|
|
Inhibitory Effects of Fenofibrate on ET-1–Induced or PMA-Induced AP-1 DNA Binding Activity
To investigate whether fenofibrate inhibits AP-1 DNA binding activity, we performed EMSA using radiolabeled oligonucleotides corresponding to AP-1 site. As shown in Figure 5A, ET-1 produced an almost 4-fold increase in AP-1 DNA binding activity. This was significantly inhibited by fenofibrate. The shifted complexes were specific for c-Jun because they were supershifted in the presence of antibody to the c-Jun and disappeared with excess unlabeled oligonucleotide. The activity of AP-1 DNA binding using mutant AP-1 oligonucleotide was hardly detected in ET-1–stimulated cardiomyocytes. The PMA (100 nmol/L)–induced AP-1 DNA binding activity was also inhibited by fenofibrate (Figure 5B).
|
In Vivo Experiments
Effect of Fenofibrate Treatment on Ventricular Hypertrophy Attributable to Pressure Overload in Rats With Aortic Banding
At 24 hours after operation, systolic arterial pressure was significantly elevated in the aortic banding (AB) groups (145±14 versus 114±7 mm Hg, AB+vehicle versus sham+vehicle). Administration of fenofibrate did not affect the elevation of arterial pressure in AB rats compared with vehicle administration (155±8 mm Hg). BWs of 3 groups (sham+vehicle, AB+vehicle, and AB+fenofibrate) were not significantly different (338±2, 332±7, and 345±3 g). LV weight and LV mass index were significantly higher in the AB+vehicle group than in the sham+vehicle group. These were significantly lower in fenofibrate-treated AB rats than in vehicle-treated AB rats (Figure 6A). Hypertrophy-related gene expression pattern was also elucidated. The level of preproET-1 and BNP mRNA expression and the ratio of the expression of ß-MHC mRNA to -MHC mRNA in the LV were higher in the AB+vehicle group than in sham-operated rats, and fenofibrate treatment decreased these parameters for alterations in AB rats (Figure 6B).
|
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
In this study, we demonstrated that activation of PPAR-
interrupted the earliest ET-1–induced events, ie, JNK activation, c-Jun phosphorylation, and c-Jun induction in cardiomyocytes. Because JNKs regulate the AP-1 DNA binding activity through phosphorylation of the 2 serine residues in the NH2-terminal region of c-Jun, 1 of the AP-1 components,19 fenofibrate, would inhibit AP-1 activity partly via JNK pathway inhibition. Activation of ERK has been implicated in features of the hypertrophic response in an in vitro model.10 Also in our study, ERKs were markedly activated by ET-1 in cardiomyocytes, but this was not affected by fenofibrate. Therefore, the inhibitory effect of fenofibrate on ET-1–related hypertrophic responses might be mediated through interfering with the JNK pathway rather than the ERK pathway.
We demonstrated that fenofibrate inhibited ET-1 promoter activity, preproET-1 mRNA expression, and hypertrophy in ET-1–stimulated cardiomyocytes. To gain additional insight into the mechanism of the PPAR-–mediated regulation of ET-1 gene expression, we focused on the effect of fenofibrate on AP-1 transcription activity, because the AP-1 site in the promoter region of the ET-1 gene is considered to be essential in the ET-1–induced transcription of ET-1. Indeed, by using p(AP-1)7-Luc vector, we confirmed that the AP-1–dependent reporter gene expression induced by ET-1 or PMA in cardiomyocytes was significantly inhibited by fenofibrate (data not shown). It has been reported that transactivation studies using c-Fos and c-Jun expression plasmids confirmed strong activation of the ET-1 promoter and that the markedly increased ET-1 promoter activity by c-Fos and c-Jun was inhibited by cotransfection of the PPAR- expression plasmid.20 PPARs have been suggested to interfere negatively with the AP-1, Stat, and nuclear factor–B signaling pathways via competition for essential cofactors.21 Therefore, it is considered that activated PPAR- binds to AP-1 or its cofactor and that AP-1 is prevented from binding to the cis-elements of the promoter region, which results in impairment of ET-1 gene induction. Thus, one possible mechanism of the inhibitory action of PPAR- activation on ET-1–induced cardiac hypertrophy seems to be through interference with AP-1 binding to its specific site in the ET-1 gene promoter region. This notion is supported by the fact that the in vitro complex formation of the AP-1 site with nuclear protein from cardiomyocytes stimulated by either ET-1 or PMA was significantly inhibited by fenofibrate.
In this study, we revealed that fenofibrate inhibited preproET-1 mRNA expression and molecular markers of hypertrophy in the LV of AB rats of pressure overload in vivo. An increase in ET-1 production has also been shown in hypertrophied hearts in various models of pressure overload.11,12 These data suggest that the ET-1 signal is involved in the development of cardiac hypertrophy by pressure overload. Therefore, a PPAR- activator may inhibit cardiac hypertrophy through suppression of the ET-1 signal in vivo as well as in vitro.
In conclusion, we demonstrated that PPAR- activation inhibits ET-1–induced cardiac hypertrophy by negative interference with AP-1, partly via JNK pathway inhibition in cardiomyocytes. Furthermore, we revealed that fenofibrate treatment inhibited LV hypertrophy and alterations in the expression of cardiac genes in the LV of AB rats in vivo. Therefore, it is possible that treatment with PPAR- activators leads to improvement in pathological myocyte hypertrophy.
|
Acknowledgments |
|---|
This study was supported by grants-in-aid for scientific research from the Ministry of Education, Science, Sports, and Culture of Japan (11357019, 11557047, 12470147, 12680012, 00005167, 14580015, 14770308, 15390077, and 15650130) and by a grant from the Miyauchi Project of Center for Tsukuba Advanced Research Alliance at the University of Tsukuba.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Kliewer SA, Forman BM, Lumberg B, et al. Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc Natl Acad Sci U S A. 1994; 91: 7355–7359.
2. Forman BM, Chen J, Evans RM. Hyperlipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors and . Proc Natl Acad Sci U S A. 1997; 94: 4312–4317.
3. Issemann I, Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature. 1990; 347: 645–650.[CrossRef][Medline] [Order article via Infotrieve]
4. Tugwood JD, Issemann I, Anderson RG, et al. The mouse peroxisome proliferator-activated receptor recognizes a response element in the 5' flanking sequence of the rat acyl CoA oxidase gene. EMBO J. 1992; 11: 433–439.[Medline] [Order article via Infotrieve]
5. Yamamoto K, Ohki R, Lee RT, et al. Peroxisome proliferator-activated receptor activators inhibit cardiac hypertrophy in cardiac myocytes. Circulation. 2001; 104: 1670–1675.
6. Miyauchi T, Masaki T. Pathophysiology of endothelin in the cardiovascular system. Annu Rev Physiol. 1999; 61: 391–415.[CrossRef][Medline] [Order article via Infotrieve]
7. Suzuki T, Hoshi H, Mitsui Y, et al. Endothelin stimulates hypertrophy and contractility of neonatal rat cardiac myocytes in a serum-free medium. FEBS Lett. 1990; 268: 149–151.[CrossRef][Medline] [Order article via Infotrieve]
8. Bogoyevitch MA, Ketterman AJ, Sugden PH. Cellular stresses differentially activate the c-Jun N-terminal protein kinases and the extracellular signal-regulated protein kinases in cultured ventricular myocytes. J Biol Chem. 1995; 270: 29710–29717.
9. Clerk A, Michael A, Sugde PH, et al. The G protein coupled receptor agonists, endothelin-1 and phenylephrine, stimulate p38 mitogen-activated protein kinase pathway in neonatal rat ventricular myocytes. J Cell Biol. 1998; 142: 523–535.
10. Sugden PH. Signaling in myocardial hypertrophy: life after calcineurin? Circ Res. 1999; 84: 633–646.
11. Miyauchi T, Yorikane R, Sakai S, et al. Contribution of endogenous endothelin-1 to the progression of cardiopulmonary alteration in rats with monocrotaline-induced pulmonary hypertension. Circ Res. 1993; 73: 887–897.
12. Yorikane R, Sakai S, Miyauchi T, et al. Increased production of endothelin-1 in the hypertrophied rat heart due to pressure overload. FEBS Lett. 1993; 332: 31–34.[CrossRef][Medline] [Order article via Infotrieve]
13. Sakai S, Miyauchi T, Kobayashi M, et al. Inhibition of myocardial endothelin pathway improves long-term survival in heart failure. Nature. 1996a; 384: 353–355.[CrossRef][Medline] [Order article via Infotrieve]
14. Sakai S, Miyauchi T, Yamaguchi I. Long-term endothelin receptor antagonist administration improves alterations in expression of various cardiac genes in failing myocardium rats with heart failure. Circulation. 2000; 101: 2849–2853.
15. Kakinuma Y, Miyauchi T, Kobayashi T, et al. Myocardial expression of endothelin-2 is altered reciprocally to that of endothelin-1 during ischemia of cardiomyocytes in vitro and during heart failure in vivo. Life Sci. 1999; 65: 1671–1683.[CrossRef][Medline] [Order article via Infotrieve]
16. Tamura K, Sudo T, Senftleben U, et al. Requirement for p38 in erythropoietin expression: a role for stress kinases in erythropoiesis. Cell. 2000; 102: 221–231.[CrossRef][Medline]
[Order article via Infotrieve]
17. Nagayama T, Tsuchiya A, Arakawa R, et al. Hypolipidemic action of fenofibrate and bezafibrate in normo- and hyper-lipidemic animals. Jpn Pharmacol Ther. 1995; 23: 181–187.
18. Jouannot P, Hatt PY. Rat myocardial mechanics during pressure-induced hypertrophy development and reversal. Am J Physiol. 1975; 229: 355–364.
19. Karin M. The regulation of AP-1 activity by mitogen-activated protein kinases. J Biol Chem. 1995; 270: 16483–16486.
20. Delerive P, Martin-Nizard F, Chinetti G, et al. Peroxisome proliferator–activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway. Circ Res. 1999a; 85: 394–402.
21. Delerive P, Bosscher DK, Besnard S, et al. Peroxisome proliferator-activated receptor negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF- and AP-1. J Biol Chem. 1999b; 274: 32048–32054.
This article has been cited by other articles:
 |
|
 |
|
  D. S. De Silva, R. M. Wilson, C. Hutchinson, P. C. Ip, A. G. Garcia, S. Lancel, M. Ito, D. R. Pimentel, and F. Sam Fenofibrate inhibits aldosterone-induced apoptosis in adult rat ventricular myocytes via stress-activated kinase-dependent mechanisms Am J Physiol Heart Circ Physiol, June 1, 2009; 296(6): H1983 - H1993. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. H. Smeets, H. M. de Vogel-van den Bosch, P. H. M. Willemsen, A. P. Stassen, T. Ayoubi, G. J. van der Vusse, and M. van Bilsen Transcriptomic analysis of PPAR{alpha}-dependent alterations during cardiac hypertrophy Physiol Genomics, December 12, 2008; 36(1): 15 - 23. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. H. Smeets, B. E. J. Teunissen, A. Planavila, H. de Vogel-van den Bosch, P. H. M. Willemsen, G. J. van der Vusse, and M. van Bilsen Inflammatory Pathways Are Activated during Cardiomyocyte Hypertrophy and Attenuated by Peroxisome Proliferator-activated Receptors PPAR{alpha} and PPAR{delta} J. Biol. Chem., October 24, 2008; 283(43): 29109 - 29118. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Doi, T. Sakoda, T. Akagami, T. Naka, Y. Mori, T. Tsujino, T. Masuyama, and M. Ohyanagi Aldosterone induces interleukin-18 through endothelin-1, angiotensin II, Rho/Rho-kinase, and PPARs in cardiomyocytes Am J Physiol Heart Circ Physiol, September 1, 2008; 295(3): H1279 - H1287. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Iemitsu, N. Shimojo, S. Maeda, Y. Irukayama-Tomobe, S. Sakai, T. Ohkubo, Y. Tanaka, and T. Miyauchi The benefit of medium-chain triglyceride therapy on the cardiac function of SHRs is associated with a reversal of metabolic and signaling alterations Am J Physiol Heart Circ Physiol, July 1, 2008; 295(1): H136 - H144. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. P. Alibin, M. A. Kopilas, and H. D. I. Anderson Suppression of Cardiac Myocyte Hypertrophy by Conjugated Linoleic Acid: ROLE OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS {alpha} AND {gamma} J. Biol. Chem., April 18, 2008; 283(16): 10707 - 10715. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J.H. Smeets, B. E.J. Teunissen, P. H.M. Willemsen, F. A. van Nieuwenhoven, A. E. Brouns, B. J.A. Janssen, J. P.M. Cleutjens, B. Staels, G. J. van der Vusse, and M. van Bilsen Cardiac hypertrophy is enhanced in PPAR{alpha}-/- mice in response to chronic pressure overload Cardiovasc Res, April 1, 2008; 78(1): 79 - 89. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. K. LeBrasseur, T.-A. S. Duhaney, D. S. De Silva, L. Cui, P. C. Ip, L. Joseph, and F. Sam Effects of Fenofibrate on Cardiac Remodeling in Aldosterone-Induced Hypertension Hypertension, September 1, 2007; 50(3): 489 - 496. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Shimojo, S. Jesmin, S. Zaedi, T. Otsuki, S. Maeda, N. Yamaguchi, K. Aonuma, Y. Hattori, and T. Miyauchi Contributory role of VEGF overexpression in endothelin-1-induced cardiomyocyte hypertrophy Am J Physiol Heart Circ Physiol, July 1, 2007; 293(1): H474 - H481. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Nakamachi, T. Nomiyama, F. Gizard, E. B. Heywood, K. L. Jones, Y. Zhao, L. Fuentes, K. Takebayashi, Y. Aso, B. Staels, et al. PPAR{alpha} Agonists Suppress Osteopontin Expression in Macrophages and Decrease Plasma Levels in Patients With Type 2 Diabetes Diabetes, June 1, 2007; 56(6): 1662 - 1670. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Jesmin, S. Zaedi, N. Shimojo, M. Iemitsu, K. Masuzawa, N. Yamaguchi, C. N. Mowa, S. Maeda, Y. Hattori, and T. Miyauchi Endothelin antagonism normalizes VEGF signaling and cardiac function in STZ-induced diabetic rat hearts Am J Physiol Endocrinol Metab, April 1, 2007; 292(4): E1030 - E1040. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y.-J. Liang, L.-P. Lai, B.-W. Wang, S.-J. Juang, C.-M. Chang, J.-G. Leu, and K.-G. Shyu Mechanical stress enhances serotonin 2B receptor modulating brain natriuretic peptide through nuclear factor-{kappa}B in cardiomyocytes Cardiovasc Res, November 1, 2006; 72(2): 303 - 312. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Shimojo, S. Jesmin, S. Zaedi, S. Maeda, M. Soma, K. Aonuma, I. Yamaguchi, and T. Miyauchi Eicosapentaenoic acid prevents endothelin-1-induced cardiomyocyte hypertrophy in vitro through the suppression of TGF-beta1 and phosphorylated JNK Am J Physiol Heart Circ Physiol, August 1, 2006; 291(2): H835 - H845. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Iemitsu, S. Maeda, S. Jesmin, T. Otsuki, Y. Kasuya, and T. Miyauchi Activation pattern of MAPK signaling in the hearts of trained and untrained rats following a single bout of exercise J Appl Physiol, July 1, 2006; 101(1): 151 - 163. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Shimojo, S. Jesmin, S. Zaedi, M. Soma, T. Kobayashi, S. Maeda, I. Yamaguchi, K. Goto, and T. Miyauchi Effect of eicosapentaenoic Acid on the different endothelin system components in endothelin-1-induced hypertrophied cardiomyocytes. Experimental Biology and Medicine, June 1, 2006; 231(6): 888 - 892. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Shimojo, S. Jesmin, S. Zaedi, M. Soma, T. Kobayashi, S. Maeda, I. Yamaguchi, K. Goto, and T. Miyauchi EPA Effect on NOS Gene Expression and on NO Level in Endothelin-1-Induced Hypertrophied Cardiomyocytes. Experimental Biology and Medicine, June 1, 2006; 231(6): 913 - 918. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Asai, K. Okumura, R. Takahashi, H. Matsui, Y. Numaguchi, H. Murakami, R. Murakami, and T. Murohara Combined therapy with PPAR{alpha} agonist and L-carnitine rescues lipotoxic cardiomyopathy due to systemic carnitine deficiency Cardiovasc Res, June 1, 2006; 70(3): 566 - 577. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Gomez-Garre, M. Herraiz, M. L. Gonzalez-Rubio, R. Bernal, P. Aragoncillo, A. Carbonell, J. J. Rufilanchas, and A. Fernandez-Cruz Activation of peroxisome proliferator-activated receptor-{alpha} and -{gamma} in auricular tissue from heart failure patients Eur J Heart Fail, March 1, 2006; 8(2): 154 - 161. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. He, J. Li, Y. Mu, R. Kuruba, Z. Ma, A. Wilson, S. Alber, Y. Jiang, T. Stevens, S. Watkins, et al. Downregulation of Endothelin-1 by Farnesoid X Receptor in Vascular Endothelial Cells Circ. Res., February 3, 2006; 98(2): 192 - 199. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. B. Tanowitz, H. Huang, L. A. Jelicks, M. Chandra, M. L. Loredo, L. M. Weiss, S. M. Factor, V. Shtutin, S. Mukherjee, R. N. Kitsis, et al. Role of Endothelin 1 in the Pathogenesis of Chronic Chagasic Heart Disease Infect. Immun., April 1, 2005; 73(4): 2496 - 2503. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. N. Petrashevskaya and A. Schwarz Peroxisome proliferator-activated receptor {beta}/{delta}: a new antihypertrophic drug target? Cardiovasc Res, March 1, 2005; 65(4): 770 - 771. [Full Text] [PDF]
|
|
|
|
|
|
A. Planavila, R. Rodriguez-Calvo, M. Jove, L. Michalik, W. Wahli, J. C. Laguna, and M. Vazquez-Carrera Peroxisome proliferator-activated receptor {beta}/{delta} activation inhibits hypertrophy in neonatal rat cardiomyocytes Cardiovasc Res, March 1, 2005; 65(4): 832 - 841. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||